Galecto is a biotechnology business based in the US. Galecto shares (GLTO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $6.71 – a decrease of 3.03% over the previous week. Galecto employs 13 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $6.71 |
|---|---|
| 52-week range | $6.61 - $23.50 |
| 50-day moving average | $11.96 |
| 200-day moving average | $15.15 |
| Wall St. target price | $225.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-23.25 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $6.73 from 2024-10-15
| 1 week (2024-10-10) | -2.75% |
|---|---|
| 1 month (2024-09-17) | -52.24% |
| 3 months (2024-07-17) | 1,086.74% |
| 6 months (2024-04-17) | 897.92% |
| 1 year (2023-10-17) | 971.83% |
|---|---|
| 2 years (2022-10-17) | 269.78% |
| 3 years (2021-10-15) | 96.78% |
| 5 years (2019-10-13) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -32.17% |
| Return on equity TTM | -75.57% |
| Profit margin | 0% |
| Book value | $21.74 |
| Market Capitalization | $8.8 million |
TTM: trailing 12 months
Galecto's shares were split on a 1:25 basis on 29 August 2024. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Galecto shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Galecto shares which in turn could have impacted Galecto's share price.
Over the last 12 months, Galecto's shares have ranged in value from as little as $6.61 up to $23.5. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Galecto's is 1.17. This would suggest that Galecto's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
To put Galecto's beta into context you can compare it against those of similar companies.
Galecto, Inc. , a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark. .
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.